News | March 07, 2011

Occlutech Wins Swedish Court Ruling Against AGA-St. Jude Medical

March 4, 2011 - Occlutech GmbH received a favorable court ruling in Stockholm, Sweden in the ongoing patent litigation case with AGA Medical-St. Jude Medical.

In the ruling by Stockholm’s Tingsratt , the district court of Stockholm, the court does not see any basis for AGA-St Jude's claim that the Occlutech atrial septal defect (ASD) and patent foramen ovale (PFO) occluders violate any patent brought forward in the litigation. The Stockholm court decision is similar to the first instance ruling in the United Kingdom, which was confirmed by the appeal court in the United Kingdom, the last one received mid-2010. The U.K. ruling is final as the U.K. supreme court did not allow an appeal requested by AGA. The favorable Stockholm ruling is also similar to first instance as well as appeal court decisions in The Hague, in the Netherlands, the last one obtained in the end of 2010.

The rulings in Sweden and The Netherlands are subject to appeal by AGA-St. Jude Medical.

Throughout the litigation, Occlutech's owners and investors have funded work in maintaining and substantially strengthening Occlutech's own patent position. In 2011 and 2012, Occlutech expects to launch additional occluders for indications such as patent ductus arteriosus (PDA) and ventricular septal defect (VSD) in addition to second generation ASD and PFO occluders. Also, an innovative left atrial appendage (LAA) occluder, a new generation of stent grafts and cardiac valve intervention technologies are being developed.

For more information: www.occlutech.com

Related Content

Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders| March 29, 2017
March 29, 2017 — For patients with...
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
Dee Dee Wang, Henry Ford Hospital, 3D printing for cardiology, 3-D

Dr. Dee Dee Wang with part of Henry Ford Hospital's collection of 3-D printed hearts used for education and to preplan structural heart procedures.

Feature | 3-D Printing| March 03, 2017
March 3, 2017 — A Henry Ford Hospital study found a 100 percent success rate in left atrial appendage (LAA) occlusion
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders| February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
Overlay Init